Urogen Pharma Ltd
NASDAQ:URGN
Urogen Pharma Ltd
Net Income (Common)
Urogen Pharma Ltd
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Urogen Pharma Ltd
NASDAQ:URGN
|
Net Income (Common)
-$102.2m
|
CAGR 3-Years
7%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Net Income (Common)
-$7m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Net Income (Common)
$8.3m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
34%
|
|
B
|
BioLine RX Ltd
TASE:BLRX
|
Net Income (Common)
-$60.6m
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-14%
|
Entera Bio Ltd
NASDAQ:ENTX
|
Net Income (Common)
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Net Income (Common)
-₪31m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-12%
|
See Also
What is Urogen Pharma Ltd's Net Income (Common)?
Net Income (Common)
-102.2m
USD
Based on the financial report for Dec 31, 2023, Urogen Pharma Ltd's Net Income (Common) amounts to -102.2m USD.
What is Urogen Pharma Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-6%
Over the last year, the Net Income (Common) growth was 7%. The average annual Net Income (Common) growth rates for Urogen Pharma Ltd have been 7% over the past three years , -6% over the past five years .